

Sisto PerdonÃ

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12061934/publications.pdf>

Version: 2024-02-01

78
papers

3,485
citations

109137

35
h-index

149479

56
g-index

79
all docs

79
docs citations

79
times ranked

4921
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies. <i>Urologia Internationalis</i> , 2022, 106, 75-82.	0.6	4
2	Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter study. <i>Minerva Urology and Nephrology</i> , 2022, 73, .	1.3	4
3	Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guérin Immunotherapy. <i>Diagnostics</i> , 2022, 12, 586.	1.3	14
4	Outcomes of Robot-assisted Partial Nephrectomy for Clinical T3a Renal Masses: A Multicenter Analysis. <i>European Urology Focus</i> , 2021, 7, 1107-1114.	1.6	17
5	Subcellular Localization of uc.8+ as a Prognostic Biomarker in Bladder Cancer Tissue. <i>Cancers</i> , 2021, 13, 681.	1.7	12
6	Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 651745.	1.3	11
7	Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 626-635.	0.6	20
8	Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project). <i>World Journal of Urology</i> , 2020, 38, 151-158.	1.2	23
9	Near-infrared Fluorescence Imaging with Indocyanine Green in Robot-assisted Partial Nephrectomy: Pooled Analysis of Comparative Studies. <i>European Urology Focus</i> , 2020, 6, 505-512.	1.6	35
10	Circulating preoperative testosterone level predicts unfavourable disease at radical prostatectomy in men with International Society of Urological Pathology Grade Group 1 prostate cancer diagnosed with systematic biopsies. <i>World Journal of Urology</i> , 2020, 39, 1861-1867.	1.2	14
11	Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 459-464.	0.8	42
12	Effect of Obesity and Overweight Status on Complications and Survival After Minimally Invasive Kidney Surgery in Patients with Clinical T ₂₋₄ Renal Masses. <i>Journal of Endourology</i> , 2020, 34, 289-297.	1.1	9
13	Robotic partial nephrectomy versus radical nephrectomy in elderly patients with large renal masses. <i>Minerva Urologica e Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 99-108.	3.9	28
14	Outcomes and predictors of benign histology in patients undergoing robotic partial or radical nephrectomy for renal masses: a multicenter study. <i>Central European Journal of Urology</i> , 2020, 73, 33-38.	0.2	3
15	An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 507-514.	1.2	77
16	Outcomes of Partial and Radical Nephrectomy in Octogenarians – A Multicenter International Study (Resurge). <i>Urology</i> , 2019, 129, 139-145.	0.5	9
17	Robotic versus laparoscopic radical nephrectomy: a large multi-institutional analysis (ROSULA) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.2	36
18	Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer. <i>European Urology Oncology</i> , 2018, 1, 403-410.	2.6	66

#	ARTICLE	IF	CITATIONS
19	Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer. <i>Journal of Cancer</i> , 2018, 9, 4250-4254.	1.2	26
20	Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 297.	3.5	11
21	Microbiota effects on cancer: from risks to therapies. <i>Oncotarget</i> , 2018, 9, 17915-17927.	0.8	155
22	Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group). <i>European Urology</i> , 2018, 74, 226-232.	0.9	109
23	Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 445-452.	0.9	55
24	Exploring the molecular aspects associated with testicular germ cell tumors: a review. <i>Oncotarget</i> , 2018, 9, 1365-1379.	0.8	21
25	Outcomes of Laparoscopic and Robotic Partial Nephrectomy for Large (>4ÅCm) Kidney Tumors: Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2017, 24, 2420-2428.	0.7	18
26	The emerging role of obesity, diet and lipid metabolism in prostate cancer. <i>Future Oncology</i> , 2017, 13, 285-293.	1.1	55
27	Epithelial-mesenchymal transition in prostate cancer: an overview. <i>Oncotarget</i> , 2017, 8, 35376-35389.	0.8	162
28	Micrnas in prostate cancer: an overview. <i>Oncotarget</i> , 2017, 8, 50240-50251.	0.8	113
29	Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer. <i>Oncotarget</i> , 2017, 8, 77110-77120.	0.8	59
30	Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance. <i>Oncotarget</i> , 2017, 8, 18424-18434.	0.8	52
31	Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX. <i>BioMed Research International</i> , 2016, 2016, 1-11.	0.9	43
32	New Cross-Talk Layer between Ultraconserved Non-Coding RNAs, MicroRNAs and Polycomb Protein YY1 in Bladder Cancer. <i>Genes</i> , 2016, 7, 127.	1.0	26
33	From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples. <i>Frontiers in Pharmacology</i> , 2016, 7, 110.	1.6	4
34	Tumour biomarkers: homeostasis as a novel prognostic indicator. <i>Open Biology</i> , 2016, 6, 160254.	1.5	21
35	Multiparametric MRI for prostate cancer detection: Preliminary results on quantitative analysis of dynamic contrast enhanced imaging, diffusion-weighted imaging and spectroscopy imaging. <i>Magnetic Resonance Imaging</i> , 2016, 34, 839-845.	1.0	21
36	Biomarkers in localized prostate cancer. <i>Future Oncology</i> , 2016, 12, 399-411.	1.1	39

#	ARTICLE	IF	CITATIONS
37	Achievement of trifecta in minimally invasive partial nephrectomy correlates with functional preservation of operated kidney: a multi-institutional assessment using MAG3 renal scan. <i>World Journal of Urology</i> , 2016, 34, 925-931.	1.2	26
38	PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance. <i>World Journal of Urology</i> , 2016, 34, 485-493.	1.2	41
39	Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review. <i>Oncotarget</i> , 2016, 7, 85641-85649.	0.8	22
40	Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis. <i>Oncotarget</i> , 2016, 7, 20636-20654.	0.8	66
41	Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy. <i>Medicine (United States)</i> , 2015, 94, e1861.	0.4	43
42	Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 163.e15-163.e23.	0.8	40
43	Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. <i>Future Oncology</i> , 2015, 11, 3091-3098.	1.1	17
44	Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine. <i>Anticancer Research</i> , 2015, 35, 1017-23.	0.5	35
45	Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 48.	3.5	24
46	Robotic Versus Laparoscopic Adrenalectomy: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2014, 65, 1154-1161.	0.9	167
47	Multiparametric MRI for prostate cancer detection: Performance in patients with prostate-specific antigen values between 2.5 and 10 ng/mL. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 39, 1206-1212.	1.9	21
48	Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with prostate-specific antigen levels at first biopsy: systematic review and meta-analysis. <i>Translational Research</i> , 2014, 164, 444-451.	2.2	48
49	Current Applications of Near-infrared Fluorescence Imaging in Robotic Urologic Surgery: A Systematic Review and Critical Analysis of the Literature. <i>Urology</i> , 2014, 84, 751-759.	0.5	47
50	Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. <i>Prostate</i> , 2013, 73, 227-235.	1.2	58
51	Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retrospective study. <i>Journal of Translational Medicine</i> , 2013, 11, 161.	1.8	36
52	EGFR mutational status in penile cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 501-505.	1.5	14
53	Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 761-765.	0.8	16
54	Regulatory T cells, interleukin (IL)-6, IL-8, Vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. <i>BJU International</i> , 2013, 112, 686-696.	1.3	70

#	ARTICLE	IF	CITATIONS
55	Comment on: EGFR mutational status in Brazilian patients with penile carcinoma. Expert Opinion on Therapeutic Targets, 2013, 17, 857-859.	1.5	2
56	Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. Future Oncology, 2013, 9, 889-897.	1.1	38
57	Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2-10 ng/ml. PLoS ONE, 2013, 8, e67687.	1.1	87
58	Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms. Oncology Reports, 2012, 27, 409-15.	1.2	17
59	Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU International, 2012, 110, E661-6.	1.3	76
60	Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clinica Chimica Acta, 2012, 413, 1274-1278.	0.5	51
61	Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU International, 2011, 107, 234-239.	1.3	82
62	Prostate Cancer Detection in the "Grey Area" of Prostate-Specific Antigen Below 10 ng/ml: Head-to-Head Comparison of the Updated PCPT Calculator and Chun's Nomogram, Two Risk Estimators Incorporating Prostate Cancer Antigen 3. European Urology, 2011, 59, 81-87.	0.9	73
63	Paclitaxel in Pretreated Metastatic Penile Cancer: Final Results of a Phase 2 Study. European Urology, 2011, 60, 1280-1284.	0.9	73
64	Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. Cancer Chemotherapy and Pharmacology, 2011, 67, 1455-1461.	1.1	24
65	Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial. Anti-Cancer Drugs, 2010, 21, 101-106.	0.7	19
66	Reply to Emmanuele A. Jannini's Words of Wisdom re: The Role of Short Frenulum and the Effects of Frenulectomy on Premature Ejaculation [J Sex Med 2010;7:1269-76]. Eur Urol 2010;57:1119-20. European Urology, 2010, 58, e49-e50.	0.9	1
67	Original Research "Ejaculatory Disorders: The Role of Short Frenulum and the Effects of Frenulectomy on Premature Ejaculation. Journal of Sexual Medicine, 2010, 7, 1269-1276.	0.3	20
68	Four-Year Outcome of a Prospective Randomised Trial Comparing Bipolar Plasmakinetic and Monopolar Transurethral Resection of the Prostate. European Urology, 2009, 55, 922-931.	0.9	97
69	Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. Anti-Cancer Drugs, 2009, 20, 277-280.	0.7	11
70	Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer. Cancer, 2008, 112, 75-83.	2.0	83
71	Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study. European Urology, 2008, 54, 1089-1096.	0.9	121
72	Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study. European Urology, 2007, 52, 1020-1027.	0.9	15

#	ARTICLE	IF	CITATIONS
73	Cyrus bipolar versus standard monopolar transurethral resection of the prostate: A randomized prospective trial. <i>Urology</i> , 2006, 67, 69-72.	0.5	120
74	Renal cell carcinoma with solitary toe metastasis. <i>International Journal of Urology</i> , 2005, 12, 401-404.	0.5	33
75	Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. <i>Lancet Oncology</i> , The, 2005, 6, 295-300.	5.1	108
76	Management of gynaecomastia in patients with prostate cancer: a systematic review. <i>Lancet Oncology</i> , The, 2005, 6, 972-979.	5.1	49
77	Dynamic sentinel node biopsy in clinically node-negative penile cancer versus radical inguinal lymphadenectomy: A comparative study. <i>Urology</i> , 2005, 66, 1282-1286.	0.5	64
78	Weekly Docetaxel and Vinorelbine (VIN-DOX) as First Line Treatment in Patients with Hormone Refractory Prostate Cancer. <i>European Urology</i> , 2004, 46, 712-716.	0.9	16